Pharmacogenetic markers of development of angioneurotic edema as a secondary side effect to enalapril in patients with essential arterial hypertension

Article type: Research Article

Authors: Sychev, Ivan V.^a; | Denisenko, Natalia P.^b | Kachanova, Anastasiya A.^c | Lapshtaeva, Anna V.^d | Abdullaev, Sherzod P.^e | Goncharova, Ludmila N.^f | Mirzaev, Karin B.^g | Sychev, Dmitry A.^h

Affiliations: [a] Department of Faculty Therapy, Ogarev Mordovia State University, Saransk, Russian Federation | [b] Research Institute of Molecular and Personalized Medicine, Department of Clinical Pharmacology and Therapy named after Academician B.E. Votchal, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation | [c] Predictive and Prognostic Biomarkers Department, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation | [d] Department of Immunology, Microbiology and Virology, Ogarev Mordovia State University, Saransk, Russian Federation | [e] Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation | [f] Department of Faculty Therapy, Ogarev Mordovia State University, Saransk, Russian Federation | [g] Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation | [h] Clinical Pharmacology and Therapy Department named after Academician B.E. Votchal, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation

Correspondence: [*] Address for correspondence: Ivan V. Sychev, Postgraduate Student, Department of Faculty Therapy, Ogarev Mordovia State University, 68 Bolshevitskaya Street, Saransk 430005, Republic of Mordovia, Russia. E-mail: sychev_iv@bk.ru

Abstract: BACKGROUND:Angioneurotic edema is the most dangerous complication in angiotensin-converting enzyme inhibitors (ACEIs) therapy. Based on the current data, the clinical and genetic predictors of angioedema development are still understudied, which demonstrates the relevance of this study. OBJECTIVE:To reveal the pharmacogenetic predictors of the angioedema as a secondary side effect to enalapril in patients with essential arterial hypertension. METHODS:The study enrolled 111 subjects randomized into two groups: study group, patients with the angioedema as a secondary side effect to enalapril; and control group, patients without adverse drug reaction. All patients underwent pharmacogenetic testing. RESULTS:An association between the development of the angioneurotic edema and the genotypes AA rs2306283 of gene SLCO1B1, TT rs4459610 of gene ACE, and CC rs1799722 of gene BDKRB2 in patients was revealed. CONCLUSION:The findings justify further investigations of the revealed genetic predictors of angioedema with larger-size patient populations.

Keywords: ACE inhibitors, enalapril, adverse drug reaction, hypertensive disease, angioedema

DOI: 10.3233/JRS-230006

Journal: International Journal of Risk & Safety in Medicine, vol. 35, no. 1, pp. 37-47, 2024